key: cord-0724038-7s5sr7pg
authors: Choi, Angela; Koch, Matthew; Wu, Kai; Dixon, Groves; Oestreicher, Judy; Legault, Holly; Stewart□Jones, Guillaume B.E.; Colpitts, Tonya; Pajon, Rolando; Bennett, Hamilton; Carfi, Andrea; Edwards, Darin K.
title: Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
date: 2021-06-28
journal: bioRxiv
DOI: 10.1101/2021.06.28.449914
sha: 0ee1f681eb408b24f183bf061660ac119f868ad1
doc_id: 724038
cord_uid: 7s5sr7pg

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated as D614G). Results showed minimal effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), B.1.617.2 (Delta), and P.1 (Gamma) showed decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273–elicited serum neutralization.

As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate in various parts of the world, several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of interest (VOIs) and variants of concern (VOCs) have emerged, including in the United States and Angola (A.VOI.V2). 1 There is growing concern over these variants based on increased transmissibility and the ability of some variants to partially escape both natural and vaccineinduced immunity. Notably, the B.1.617.2 lineage was recently classified as a VOC by the World Health Organization due to evidence of an increased rate of transmission, reduced effectiveness of monoclonal antibody treatment, and reduced susceptibility to neutralizing antibodies. 1 We previously reported that mRNA-1273, a lipid nanoparticle encapsulated mRNA-based vaccine encoding the spike glycoprotein of the SARS-CoV-2 Wuhan-Hu-1 isolate, induced high neutralizing antibody titers in phase 1 trial participants 2 and was highly effective in preventing symptomatic and severe COVID-19. 3, 4 Some VOCs or VOIs, including B.1.351 and P.1, reduced neutralizing antibody levels using a pseudovirus-based model. 5 Importantly, however, all variants remained susceptible to mRNA-1273 vaccine-elicited serum neutralization. 5 Here we provide an update on the neutralization activity of vaccine sera against several newly-emerged variants, including the Delta variant B.1.617.2.

Participants were immunized with 100 µg mRNA-1273 on a prime-boost schedule and sera was collected 7 days post boost (day 36). Study protocols and results are reported previously. 2

Codon-optimized full-length spike (S) protein of the original Wuhan-Hu-1 variant with D614G mutation (D614G) or the S variants, listed in Table 1 , were cloned into a pCAGGS vector. To make SARS-CoV-2 full-length S pseudotyped recombinant VSV-ΔG-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S-expression plasmid and subsequently infected with VSV∆G-firefly-luciferase as previously described. 6 For the neutralization assay, serially diluted serum samples were mixed with pseudovirus and incubated at 37 °C for 45 minutes. The virus-serum mix was subsequently used to infect A549-hACE2-TMPRSS2 cells 7 for 18 hours at 37 °C before adding ONE-Glo reagent (Promega) for measurement of the luciferase signal by relative luminescence units (RLUs). The percentage of neutralization was calculated based on the RLUs of the virus-only control, and subsequently analyzed using fourparameter logistic curve in Prism v.8 (GraphPad Software, Inc.).

Two-sided Wilcoxon matched-pairs signed rank test was used to compare the same patients against different viruses. Statistical analyses were performed (Prism v.8). Geometric mean titers, lower limit of quantification, and fold change to D614G were included.

We assessed neutralization activity of sera against D614G pseudovirus (predominant variant in 2020), B. 1.1.7, B.1.1.7 + E484K, B.1.427/B.1.429, P.1, B.1.351-v1, B.1.351-v2, B.1.351-v3,   B.1.526, B.1.617.1-v1, B.1.617.1-v2, B.1.617.2, A.23.1-v1, A.23.1-v2, B.1.525, (Figure 1) . In contrast, all other variants examined showed decreased neutralization titers compared with D614G (Figure 1 Table 1) . The reciprocal neutralizing titers on the pseudovirus neutralization assay at a 50% inhibitory dilution

World Health Organization. Weekly epidemiological update on COVID-19 -11

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Whisker end points are equal to the maximum and minimum values below or above the median at 1.5 times the IQR. The GMT fold change over D614G for each variant is shown below. In Panel B, the colored lines connect the D614G and variant neutralization titers in matched samples

GMT, geometric mean titer; ID 50 , 50% inhibitory dilution factor

VOC, variant of concern